Alembic Pharmaceuticals gained 0.13% to Rs 599 after consolidated net profit jumped 37.89% to Rs 234.19 crore on 18.75% rise in net sales to Rs 1,209.13 crore in Q3 December 2019 over Q3 December 2018.
Consolidated profit before tax (PBT) rose 31.09% to Rs 276.28 crore in Q3 December 2019 as compared to Rs 210.75 crore in Q3 December 2018. The Q3 result was declared during trading hours today, 22 January 2020.
Commenting on the Q3 performance, Pranav Amin, the managing director of Alembic Pharmaceuticals, has stated that, It was a good quarter for the company led by strong growth in the International Markets. We launched 7 products in the US market during the quarter.
Alembic Pharmaceuticals is engaged developing formulations and active pharmaceutical ingredients (API).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
